Vir(US:VIR)2025-08-06 20:30Oncology Programs - Vir Biotechnology is developing potential best-in-class programs across oncology, targeting solid tumors such as HER2, PSMA, and EGFR [12] - VIR-5818 (HER2) showed a 33% response rate and 100% biomarker response in metastatic colorectal cancer (mCRC) at early doses [57] - VIR-5500 (PSMA) demonstrated 100% PSA decline and 58% PSA50 responses at early doses in prostate cancer [57] - VIR-5818 (HER2) showed a molecular response in 54% of subjects based on ctDNA analysis [91, 94] Hepatitis Delta Program - An estimated 61,000 patients in the U S have active viremic HDV infection [22] - Tobevibart + elebsiran combination therapy showed 41% of participants achieving HDV RNA <Target Not Detected (0 IU/mL) at 24 weeks and 64% at 36 weeks in P2 trial [36] - 90% of participants receiving tobevibart + elebsiran achieved HBsAg <10 IU/mL, compared to only 22% with tobevibart monotherapy Q2W at Week 24 [41] - The ECLIPSE registrational clinical trials for Hepatitis Delta are actively enrolling [48] Financial Status - Vir Biotechnology had approximately $892 million in cash and investments as of June 30, 2025, providing a cash runway into mid-2027 [12, 144] - Total revenues for the three months ended June 30, 2025, were $12 million, a 61% decrease compared to $31 million for the same period in 2024 [142]